Quality Overall Summary Software: Test Source Consistency

Publisher disclosure: Assyro publishes this guide and places itself first as an editorial recommendation. Product descriptions are documentary assessments of official materials checked September 14, 2026, not results from comparative software testing. The CMC packet below is a fictional evaluation exercise.

This guide addresses the CMC regulatory lead preparing a medicinal-product marketing application. The buying task is specific: keep the Quality Overall Summary, or QOS, in Module 2.3 consistent with the selected quality dossier. It is not a comparison of entire regulatory information management systems, and it does not determine the scientific adequacy of a product's specifications.

Shortlist by what the product actually claims to do

Compare the named application or authoring module, not everything its vendor sells. A document repository, drafting engine, and content QC tool can contribute to the workflow without being interchangeable.

This is a compact evaluation shortlist, not an exhaustive market ranking. No candidate receives credit for an unshown export, an unspecified integration, or a document type inferred from a neighboring workflow.

Fix the M4Q version before comparing demonstrations

A vendor can show a well-organized document using the wrong structure for your intended application. Record the authority, application type, product scope, and agreed template revision before the pilot.

The worked example here uses ICH M4Q(R1), Step 4 version dated September 12, 2002. Its QOS follows the scope and outline of Module 3, and should not introduce information or justifications absent from Module 3 or elsewhere in the CTD. Sections 2.3.S.4 and 2.3.P.5 address control of drug substance and drug product respectively, drawing on the corresponding detailed quality content. See M4Q(R1), section 2.3 and its control subsections.

M4Q(R2) remains a draft in the primary materials checked for this guide. FDA's January 2026 entry labels it draft guidance, not for implementation. The attached document identifies the ICH draft endorsed May 14, 2025. FDA M4Q(R2) status and draft

EMA's M4Q(R2) Step 2b document carries a June 19, 2025 cover and the same May 14 ICH draft. Its proposed Module 2.3 organization differs materially from R1, including core quality information and development summaries and justifications. Treat a vendor's R2 demonstration as a demonstration against a named draft, with a separate decision about whether that format applies to your submission.

Keep current-use acceptance separate from future-readiness assessment. You may value a vendor's ability to trial a future structure while retaining a currently applicable template for production. Also keep content structure separate from the electronic submission format: supporting an eCTD version does not, by itself, demonstrate QOS scientific consistency.

What “source-traceable” should mean in a QOS evaluation

A reference that opens a document is useful, but it leaves several questions unanswered. Is it the selected version? Does it concern the right substance manufacturer or product presentation? Does the cited table support the whole sentence, or only one value?

Ask the demonstrator to start from a material statement in the summary and show three connections: the corresponding Module 3 passage or table, the quality source supporting it, and the decision identifying those versions as the ones selected for this dossier. Then reverse the direction. Change the source and inspect which summary passages become candidates for review.

The reverse check matters because a statement can remain perfectly linked to a superseded source. A green citation indicator does not tell you that the current dossier is internally consistent.

Your evaluation should also distinguish extraction from interpretation. A tool may correctly reproduce a test result yet overstate the conclusion, for example by turning one batch result into a claim about every batch. Require the source to support the extent of the sentence as well as its number. The relevant reviewer owns the scientific judgment; the software should expose what that judgment rests on.

Use the source-traceability checklist to test whether a valid citation supports the full quality-summary statement.

Four product assessments for the QOS task

Assyro: a conditional fit for the controlled dossier workflow

Assyro is our starting recommendation when the QOS needs to remain coordinated with document review and downstream submission work. Its document-management page describes controlled versions, tracked review and approval, and links between documents and submission context. Those are relevant capabilities to investigate when the team cannot reliably identify which QOS and Module 3 versions belong together.

The condition is that dedicated QOS generation and semantic source reconciliation must be proven separately. This guide does not establish an available Assyro workflow that automatically derives every Module 2.3 claim from a quality packet. It also does not infer scientific correctness from a structural submission check.

Use the pilot to inspect a pair of documents: the selected Module 3 control section and its QOS summary. Ask the team to identify the approved baseline, propose a working revision, and show the record when one source changes. Distinguish what the application detects from the reconciliation your writer performs manually. Both can form part of a usable process, but the proposal should make the division explicit.

The buying advantage to investigate is coordination of the document lifecycle. The tradeoff is that a separate drafting or specialist QC component may still be needed. If your non-negotiable requirement is automatic QOS drafting from controlled CMC sources and that cannot be demonstrated, Assyro remains a possible document-workflow component rather than a demonstrated replacement for that authoring task.

AlphaLife AuroraPrime RMA: QOS authoring with change and review orchestration

AlphaLife's AuroraPrime RMA document-type page explicitly names both Module 2.3 QOS and Module 3 quality content. It describes outline preparation, evidence-linked draft generation, role-based reviews, conflicting-comment handling, and upstream change analysis. This is direct QOS scope, rather than a conclusion drawn from the product's clinical-writing functions.

For a CMC team, the useful distinction is the connection between drafting and change review. The question is whether the system can identify precisely what changed without spreading a substance-specific update across unrelated product content.

Ask for a demonstration in which two reviewers disagree. One accepts the new specification source for the working dossier; another identifies that the detailed justification section has not been updated. The software should make the disagreement and affected passages visible. A conflict-resolution feature is valuable only if the team can preserve the technical decision and its rationale, not merely clear a comment count.

Confirm which RMA configuration, template setup, source formats, and export deliverables the proposal includes. The public QOS description does not establish your exact product modality, regional template, or file fidelity. Have the vendor show a complete review copy using your table structure and source references. Evaluate the QOS workflow on its own evidence; speed figures or successful demonstrations for CSRs should not be transferred to CMC work.

The AuroraPrime RMA alternatives guide examines cross-document change control beyond the QOS-specific source exercise.

SyncIQ Regulatory Atlas: an explicit QOS-to-Module 3 consistency claim

SyncIQ's Regulatory Atlas page describes QOS summaries and Module 3 sections drafted from batch records, certificates of analysis, and stability data. It says values link to source pages and cross-module inconsistencies are flagged. The page also identifies Regulatory Atlas as the product previously called Dossier Atlas; these are not two separate candidates.

That documented focus makes it a relevant option when the main buying criterion is source-to-summary reconciliation. It also supplies a claim you can challenge directly: give the system a source that is valid for one context but unsuitable for another.

For example, include a product batch certificate alongside a substance specification containing a similarly named test. The pilot should preserve the entity, test purpose, criterion, and source version rather than selecting whichever table has the closest words. Inspect the cited page and the specific row, including any basis or footnote. A correct document citation attached to the wrong cell still fails the exercise.

Regulatory Atlas describes standalone authoring, review, refinement, and export, with integrations available for the surrounding environment. Confirm the actual receiving system and output contract instead of assuming the drafting workflow completes your publishing process. Its source-link and inconsistency claims justify a targeted pilot; they do not establish a measured detection rate for your documents. Retain the misses as well as the flagged discrepancies when deciding whether the remaining manual review is acceptable.

DDi CMC Authoring Solutions: assess the components before buying a suite

DDi's CMC Authoring Solutions page describes an Authoring Agent for first drafts, summaries, and structured data-to-text work, and a QC Agent for content, data, and formatting checks. Its separate QC automation page also identifies CMC cross-document alignment. That supports considering DDi for a drafting or reconciliation component.

It does not settle whether your proposal includes an end-to-end QOS authoring workflow. Ask DDi to name the product and components being licensed, identify the QOS sections included, and separate them from document management, formatting, or publishing products. Avoid treating REGai, smartDOC, and other vendor offerings as one automatic entitlement.

DDi is particularly relevant to evaluate if your team intends to keep its existing authoring environment and add targeted QC or data-to-text functions. Bring an existing QOS and Module 3 section rather than asking for a fresh generic document. Have the vendor show what it can ingest and what comes back: a revised file, a proposed edit, a discrepancy report, or a task for a writer.

The tradeoff is responsibility at the interfaces. If a QC report flags a specification mismatch, someone still has to decide which source applies, correct the right document, and rerun the check. Confirm that this loop is included in the proposed process and price. A useful component can be a better fit than a larger replacement, provided its exact limits and owners are agreed.

A synthetic CMC packet that exposes a stale specification

Use this exercise to test document consistency and provenance. All entities and identifiers are fictional. The acceptance-criterion tokens below deliberately contain no numerical limits: they stand for complete criterion text that you would supply in a real, authorized pilot. They are not usable specifications or manufacturing instructions.

The example concerns substance EX-S from manufacturer S-A and product EX-P, presentation P-A. The current working QOS uses an R1 template. Its selected detailed sections are 3.2.S.4 for substance control and 3.2.P.5 for product control.

Use “approved” precisely: source approval, dossier release, and an authority's decision are different states. In this exercise, approval describes sponsor-controlled records. No regulatory approval or authorization to implement a manufacturing change is implied.

Establish what each source is allowed to support

In the baseline demonstration, ask the vendor to produce or review the two QOS control subsections. The substance row should preserve DS-AC-A / DS-METHOD-01 and the product row DP-AC-A / DP-METHOD-03. Each should lead to its own Module 3 section and source specification.

This establishes a positive case and a useful near-match trap. The test name is identical, but the entities and criteria differ. A text-matching system should not harmonize those rows merely because they share a heading.

In your real packet, inspect the complete criterion: comparator, value, unit, basis, conditions, and footnotes where present. Check separately whether a row is a specification, a batch result, or a study observation. Do not allow a measured value to become an acceptance criterion through summarization.

Change the substance source while Module 3 remains stale

Introduce S-SPEC revision 2, selected by the fictional CMC owner for the next working dossier. Its criterion token is DS-AC-B and its method DS-METHOD-02. The drug-product specification has not changed. For the first part of this exercise, deliberately leave M3-S4 and QOS at revision 1.

There is now a discrepancy at two interfaces: the selected substance specification disagrees with Module 3, and the QOS still reflects the earlier Module 3 content. A system that changes only the summary may produce a newer-looking QOS while leaving it inconsistent with the dossier it summarizes.

The expected result is a review issue that names all three versions and the affected substance content. Proposed edits may be useful, but the workflow should not present the affected QOS subsection as resolved while the supporting detailed section remains unresolved. Preserve the prior approved baseline; source selection for a working revision is not permission to overwrite a released dossier.

Also withhold the updated specification justification at this stage. The writer should receive a clear gap to resolve. The software must not invent why DS-AC-B is scientifically appropriate, characterize it as tighter or safer from its identifier, or infer that the method change is validated.

Resolve the source gap and inspect the resulting summary

For the final stage, the CMC owner supplies the reviewed updates to the detailed specification, procedure, and justification content in M3-S4 revision 2, with the supporting records identified. Your subject-matter reviewers assess those records before approving them for the dossier. The synthetic exercise specifies their provenance relationship; it does not supply or validate a scientific justification.

The expected source map for the new QOS working revision is:

QOS 2.3.S.4 → M3-S4 revision 2 → S-SPEC revision 2 and its supporting records.

The product relationship stays:

QOS 2.3.P.5 → M3-P5 revision 2 → P-SPEC revision 5 and its supporting records.

Ask the vendor to retain a completed change record like this one:

Finally, add a spreadsheet labeled only “specification,” with a bare number and no product identity, unit, method, or approval state. The correct action is to request clarification or exclude it from the affected drafting step with a recorded reason. A familiar-looking value is not permission to choose its meaning.

Draft a Module 3 passage before summarizing it

A source-consistency check starts with existing text. Add a second exercise that starts with records: can the proposed authoring workflow produce a narrow, supportable Module 3 passage, then carry its meaning into the QOS? Use the complete fictional packet below in an isolated evaluation workspace. These are editorial fixtures and expected answers, not output from a tested vendor. “Approved” means approved within the fictional sponsor's document process, not approved by a regulator.

The exercise uses M4Q(R1), Step 4, September 12, 2002: substance batch analyses belong in 3.2.S.4.4, product batch analyses in 3.2.P.5.4, with corresponding summaries in 2.3.S.4 and 2.3.P.5. This is a drafting excerpt, not a complete section or submission. ICH M4Q(R1), batch-analysis and QOS control sections

Give the demonstrator this source packet

Copy these snippets into separate records, retaining their identifiers and locators. All names, results, and approval states are synthetic. Attribute Z is an invented measurement label; the numbers are batch results, never acceptance limits.

SELECT-02, revision 1, approved; page 1, selection register

“

For this working exercise, select DS-BA-03 revision 3 and DP-BA-04 revision 2. DS-BA-03 revision 2 is superseded and retained for history only. NOTE-07 is unapproved and excluded from drafting. No specification, acceptance criterion, analytical validation report, or batch-use history is supplied. Selection owner: CMC lead.

DS-BA-03, revision 3, approved; page 2, table 1

“

Entity: drug substance EX-S; manufacturer S-A. Measurement: Attribute Z; procedure Z-S, revision 2; reporting basis: as-is mass fraction. Batch DS-101 result: 0.005 g/g. Batch DS-102 result: 0.006 g/g. These values replace the corresponding entries in revision 2. This excerpt contains no conclusion about specification compliance.

DS-BA-03, revision 2, superseded; page 2, table 1

“

Entity: EX-S/S-A. Attribute Z; procedure Z-S, revision 2; as-is mass fraction. DS-101 result: 0.050 g/g. DS-102 result: 0.006 g/g. Historical record only; not selected by SELECT-02.

DP-BA-04, revision 2, approved; page 3, table 2

“

Entity: drug product EX-P; tablet presentation P-A; batch DP-201. Measurement: Attribute Z; procedure Z-P, revision 1. Result: 2 mg/tablet. This is a product result, not a drug-substance concentration. No tablet mass or substance-to-product conversion relationship is supplied.

NOTE-07, unapproved; line 1

“

Attribute Z: 6.0. Entity, batch, unit, method, and reporting basis not recorded.

The starting QOS working excerpt, QOS-TRAIN revision 0, reads: “For EX-S/S-A, DS-101 and DS-102 contain 50 and 6 mg/g of Attribute Z and meet specification.” It has no current source map. Treat this as text to correct, not an approved conclusion.

Ask for three outputs, then inspect the answer

Ask the demonstrator to draft the EX-S/S-A batch-analysis excerpt using only selected records, produce a claim-to-source map, and propose the corresponding QOS correction. Require original units beside any converted values. Keep unresolved questions in a separate review log. Do not permit unsupported placeholders to become finished submission text.

An acceptable editorial Module 3 answer is:

“

DS-BA-03 revision 3 reports Attribute Z results for EX-S manufactured by S-A using procedure Z-S revision 2. On the stated as-is basis, results were 0.005 g/g for DS-101 and 0.006 g/g for DS-102. These correspond to 5 and 6 mg/g respectively. [Source: DS-BA-03 revision 3, page 2, table 1; selected by SELECT-02 revision 1.]

The conversion is inspectable: 0.005 g/g × 1,000 mg/g = 5 mg/g, and 0.006 g/g × 1,000 mg/g = 6 mg/g. The factor converts the numerator from grams to milligrams; the denominator remains one gram of sample. It does not change an as-is result into a dry-basis result.

Keep DP-201's 2 mg/tablet out of this substance paragraph. Its destination, if separately drafted, is the product batch-analysis excerpt. Do not average these results or convert between them without the missing relationship and context. Reject NOTE-07: matching the number 6 does not establish its meaning.

Compare a failed draft with a corrected handoff

This deliberately failed answer combines several buying risks:

“

Both substance batches contain 50 mg/g of Attribute Z, below the 2 mg/tablet limit. The validated method confirms that all batches comply.

The first value comes from the superseded record; the second batch has been misreported. A product result became a limit in incompatible units. Neither method validation nor compliance is established by the packet. Fluent wording cannot repair those source-selection and interpretation failures.

After the CMC reviewer accepts the bounded Module 3 excerpt as M3-TRAIN revision 1, the proposed QOS correction is:

“

For EX-S/S-A, the reported Attribute Z results for DS-101 and DS-102 are 5 and 6 mg/g on an as-is basis, respectively (original results: 0.005 and 0.006 g/g). See 3.2.S.4.4, M3-TRAIN revision 1, supported by DS-BA-03 revision 3, page 2, table 1.

Record the change from QOS-TRAIN revision 0 to working revision 1: correct DS-101, retain DS-102, remove the unsupported compliance conclusion, and add the selected evidence chain. Retain revision 0 for history. Leave product content unchanged. QOS synchronization follows the reviewed detail; it should not introduce a new justification absent from the dossier. ICH M4Q(R1), section 2.3

Score the evidence, including what remains unknown

Record pass, fail, or unknown against each row, with the output location and reviewer initials. A writing demonstration passes only when its applicable drafting checks pass; missing scientific evidence still blocks dossier release.

Keep this packet and scorecard with the vendor evaluation. Record which steps the software performs and which the reviewer supplies. The result should identify the authoring scope you can buy today, including any specialist drafting or review work still required.

Turn the demonstration into a purchase decision

Judge the whole revision, including source preparation and reviewer corrections. Retain the input register, baseline output, new output, discrepancy record, and export. Ask a CMC colleague who did not watch the demonstration to follow one changed substance statement and one unchanged product statement back to their sources.

If that colleague cannot identify the selected version or distinguish an approved record from a proposal, the evidence handoff is incomplete. Record whether the problem arose during source classification, extraction, dossier mapping, drafting, review, or export. Correct the demonstrated failure point and repeat the same case. Do not respond to a reproducible mapping failure only by instructing reviewers to be more careful.

For a component purchase, define who closes each gap. A QC tool may correctly flag the mismatch while your writer owns the correction. For a fuller authoring purchase, require a working transition from the finding to the revised section and a retained decision. The same scientific acceptance standard applies; the allocation of work differs.

Include one more context test if it affects your program: two manufacturers, two strengths, different presentations, or different specification purposes. Select the distinction your sources actually contain. Do not reward a tool for forcing uniformity where the approved source package intentionally distinguishes contexts.

For example, if your product packet contains separate release and shelf-life criteria, include both with their explicit labels. Ask the reviewer to verify that the QOS preserves which criterion applies to which context. The system should not select the smaller value, the later upload, or the first matching test name as a substitute for that context.

Carry the agreed source and output requirements into the AI writing RFP workbook before scoring optional features.

Agree the output, implementation work, and cost boundary

Before signing, identify the authoring deliverable: an editable draft, reviewed Word document, PDF, structured data export, or a combination. Open the actual sample in the receiving workflow. Check symbols, table headers, footnotes, references, and the text around every changed criterion. A source-linked application screen does not establish that the exported document retains its meaning.

Agree how source documents remain accessible after a vendor contract ends, including version identifiers and review decisions. Decide which evidence belongs in the authoring record and which belongs in the submitted dossier. Do not automatically expose every internal source or comment in a recipient-facing export.

Ask for separate costs for template configuration, source preparation, migration, implementation support, external-reviewer access, and any additional QC or publishing product. Define whether the price covers one QOS, multiple presentations, revised versions, and subsequent application work. No public price in this guide substitutes for that scoped quote.

R2 preparation deserves its own deliverable and budget assumption. Ask who maintains the mapping, what happens when the draft changes, and how prior documents remain available. A future-template experiment should not silently alter the format selected for an active dossier.

Select the workflow that survives the source change

Evaluate Assyro first when controlled dossier coordination is central, with dedicated QOS functions subject to demonstration. AuroraPrime RMA warrants a pilot for its explicit QOS authoring and review/change workflow. Regulatory Atlas warrants one for its explicit QOS-to-Module 3 source links and inconsistency checks. DDi is relevant when CMC drafting or QC components can improve an existing process, after confirming exact QOS coverage.

Use the synthetic packet to state your must-haves before booking an Assyro document-workflow demonstration or an alternative vendor session. A satisfactory result is specific: the substance summary changes for the right reason, the product summary stays correct, the detailed dossier agrees, and a reviewer can reconstruct the decision. Select the product and implementation scope that can show that result on your evidence.

Use Assyro’s regulatory-writing overview to frame the Module 2.3 discussion, keeping QOS-specific fit conditional on the evidence described here.